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• Patients with chronic obstructive pulmonary disease and a 
stable daytime PaO2 of  55 mmHg (7.3kPa) live longer and 
have a better quality of life if provided with long-term 
continuous oxygen therapy.
• It is reasonable to offer continuous oxygen therapy also to 
patients with other lung diseases that cause chronic 
hypoxaemia.
• Indications for supplemental oxygen therapy during exercise 
(ambulatory oxygen therapy) and sleep (nocturnal oxygen 
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D iciliary oxygen therapy is an effective but potentiallypensive and inconvenient intervention. It should beescribed only for patients in whom there is evidence of
ch as those whose disability relates to a chronic reduced
arterial oxygen concentration (chronic hypoxaemia).
The most common cause of chronic hypoxaemia in Australia and
New Zealand is chronic obstructive pulmonary disease (COPD).
In hypoxaemic COPD, domiciliary oxygen is the only therapy
(apart from smoking cessation) that reduces mortality (E1).3-6







cancer or cystic fibrosis,  and, in general, any illness of which
chronic hypoxaemia is an important feature. In the absence of
hypoxaemia, oxygen therapy is unlikely to contribute usefully to
relief of dyspnoea. Home oxygen therapy for patients with
chronic heart failure and/or angina is not well supported by
evidence of efficacy, and reduced mortality with this therapy has
not been verified. An inspired-oxygen concentration of 50%
may modestly improve exercise duration in heart failure,9 but
concentrations this high are difficult to attain with current home
delivery systems.
Indications for oxygen therapy
Continuous oxygen therapy (at least 15 hours/day)
Long-term continuous oxygen therapy should be considered for
patients with stable chronic lung disease, particularly COPD, who
have an arterial partial pressure of oxygen (PaO2) consistently
 55 mmHg (7.3 kPa) when at rest, awake and breathing air. At
assessment (see Investigations), the patient’s condition must be
stable, and all reversible factors (such as anaemia) should be
remediated.10 Because gas exchange may improve substantially on
ceasing smoking, assessment should be made at least a month after
the patient has stopped smoking.
Polycythaemia (haematocrit > 0.55), clinical or electrocardio-
graphic evidence of pulmonary hypertension and/or episodes of
right heart failure reflect the systemic effects of chronic hypoxae-
mia and strengthen the case for therapeutic oxygen use. Patients
with these complications should be prescribed continuous oxygen
therapy if their stable PaO2 is 56–59 mmHg (7.4–7.8 kPa). In
COPD, continuous oxygen therapy is of most benefit for patients
with increased arterial partial pressure of carbon dioxide (PaCO2)
(> 45 mmHg or 6 kPa).4,11
As benefit has been shown to increase with increasing daily use
of oxygen,4 patients should be advised to use oxygen whenever
the physical restriction imposed by the therapy is not onerous. In
two landmark randomised controlled trials, patients who were
prescribed continuous oxygen therapy managed to use it for an
average of 18 hours a day.3,4 These patients had reduced mortality
compared with those using the oxygen 15 hours a day or less.
Thus, the recommendation is generally that the oxygen be used
for as many hours out of 24 as possible, within reason. The
benefit of daytime oxygen use, which may restrict mobility, must
be weighed against the benefit of exercise, which can improve
quality of life (E1).12
This position statement is a consensus statement based on 
evidence from English-language publications up to 2004 obtained 
by searching MEDLINE and EMBASE with the keywords 
domiciliary, home, long term and oxygen. We retrieved and 
reviewed 417 articles. We prepared the position statement, which 
was then reviewed and revised in consultation with the Clinical 
Care and Resources Subcommittee and the executive of the 
Thoracic Society of Australia and New Zealand (TSANZ). It was 
endorsed in December 2004 by the executive of the TSANZ. We 
made minor modifications after independent peer review via the 
Medical Journal of Australia. These changes were once again 
endorsed by the Clinical Care and Resources Subcommittee of the 
TSANZ. This is an update of the position statement published in 
the Journal in 19981 and has a currency of 5 years from the date of 
publication (unless superseded). We used the National Health and 
Medical Research Council’s four levels of evidence (Levels I–IV, 
designated here E1–E4).2ber 12 • 20 June 2005 621
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Intermittent or ambulatory oxygen therapy may be used as part of
continuous oxygen therapy, in which case its benefits are those of
long-term oxygen therapy. The known benefits of pulmonary
rehabilitation on exercise capacity and quality of life in COPD
patients (E1)12 support the use of ambulatory oxygen therapy in all
mobile patients on long-term oxygen therapy to allow them to
achieve their full potential in terms of these benefits as well as the
reduced mortality from continuous oxygen therapy.
The subject of ambulatory oxygen use in patients who do not
fulfil criteria for continuous oxygen therapy is controversial. A
recent Cochrane review of the subject found that no firm conclu-
sions could be made from available evidence about the effective-
ness of this intervention in patients with COPD and only mild
hypoxaemia.13
Nonetheless, it is known that ambulatory oxygen therapy may
rapidly improve exercise capacity in patients with fibrotic or
obstructive lung diseases, and benefit may occur irrespective of
resting or exercise-induced hypoxaemia. Although there is no
direct evidence that treatment of exercise-induced hypoxaemia
retards long-term pulmonary hypertension or prolongs life, it
may improve quality of life in patients who experience signifi-
cant arterial oxygen desaturation during exercise (SpO2 88%).
A recent randomised crossover trial suggested that modest
benefits in terms of emotional and social function, anxiety and
depression levels and dyspnoea could be achieved in mildly
hypoxaemic COPD patients who experienced desaturation with
exertion (E2).14 In that trial, rapid beneficial response to
supplemental oxygen did not predict longer-term benefits in
quality of life, and our consensus view, in the absence of further
data, is that evidence of short-term benefit should be demon-
strated before this therapy is recommended. Our view is
supported by the consensus statements of both the American
Thoracic Society and the Royal College of Physicians, UK.7,15
Benefit should be established by comparing exercise endurance
and degree of dyspnoea when breathing oxygen and when
breathing air (using a 6-minute walk test, treadmill, stationary
bicycle, or similar endurance test). Room air is probably
adequate for this comparison, as there appears to be no
difference in exercise endurance between breathing room air
and cylinder air.16
Ambulatory oxygen therapy may be particularly useful for
patients in rehabilitation programs, including those awaiting lung
transplantation or lung reduction surgery, to maintain an increased
level of fitness and thus improve their prognosis.
Other patients for whom intermittent oxygen therapy is indi-
cated include:
• Patients with acute asthma living in isolated areas or prone to
sudden life-threatening episodes while they are awaiting medical
attention;
• Patients who become significantly hypoxaemic during air
travel, particularly long-distance flights. Commercial passenger
aircraft operate at cabin pressures equivalent to pressures at about
1500–3000 m above sea level, with pressures of at least 2500 m
altitude equivalent likely to be experienced for a significant time.
This is analogous to breathing 15% oxygen at sea level.17 At this
“altitude”, the PaO2 for healthy people falls to around 53–
64 mmHg, with corresponding oxygen saturations of 85%–91%.17
As a general rule, supplemental oxygen is unlikely to be required if
the resting oxygen saturation is  95%, and will be required by
patients who qualify for continuous oxygen therapy at home
(SpO2 88%). Patients with oxygen saturation values between
88% and 95% can be tested for the effects of 15% oxygen in the
laboratory before a flight. The American Thoracic Society currently
recommends that PaO2 during air travel should be maintained at
> 50mmHg (6.6 kPa). PaO2 at altitude can be estimated from PaO2
at sea level by means of published nomograms.17 Further, those
travelling to high-altitude destinations may need an increase in
their oxygen prescription during their sojourn.7
• Patients with intractable dyspnoea due to terminal illnesses,
including late-stage lung disease, who have significant hypoxae-
mia. In these patients, who will usually have a life expectancy of
less than 3 months, supplementary oxygen may provide sympto-
matic relief.
Nocturnal oxygen therapy
Isolated episodes of hypoxaemia during sleep due to hypoventila-
tion or worsening ventilation–perfusion inequality in patients with
obstructive or fibrotic lung diseases should be distinguished from
hypoxaemia associated with sleep apnoea caused by upper airway
obstruction or obesity hypoventilation syndrome. Apnoea syn-
dromes are diagnosed by overnight polysomnography, and generally
require other forms of therapy (such as continuous positive airway
pressure or nocturnal ventilation) rather than supplemental oxygen.
In the absence of a high clinical pre-test probability of obstructive
sleep apnoea or obesity hypoventilation syndrome, simple nocturnal
oximetry is probably adequate to confirm isolated nocturnal hypox-
aemia in COPD. Such isolated nocturnal hypoxaemia should be
Position on continuous oxygen therapy
Continuous oxygen therapy is indicated to improve longevity and 
quality of life when
• stable daytime PaO2  55 mmHg (7.3 kPa) at rest (E1); or
• stable daytime PaO2 is 56–59 mmHg (7.4–7.8 kPa) and there is 
evidence of hypoxic organ damage (including right heart failure, 
pulmonary hypertension or polycythaemia) (E1).
Flow rate should be set to maintain PaO2 > 60 mmHg (8 kPa) (oxygen 
saturation level, measured by pulse oximetry [SpO2] > 90%) during 
waking rest. This will usually need to be increased by 1 L/min during 
sleep, exertion or air travel (E4).
Position on intermittent oxygen therapy
• Ambulatory oxygen therapy may improve quality of life in patients 
who experience significant arterial oxygen desaturation during 
exercise (SpO2  88%) (E2).
• It is recommended that rapid improvements in dyspnoea or 
exercise capacity in response to oxygen therapy be demonstrated 
before this treatment is prescribed (E4).
• Ambulatory oxygen therapy may be useful for patients in 
rehabilitation programs, including those awaiting lung 
transplantation or lung reduction surgery, to maintain an 
increased level of fitness and thus improve their prognosis (E4).
• A small cylinder of oxygen for emergency use by the patient with 
severe asthma who is prone to sudden life-threatening episodes is 
recommended (E4).
• Home oxygen therapy may be appropriate to relieve symptoms in 
terminally ill patients, who will usually have a life expectancy of less 
than 3 months (E4).622 MJA • Volume 182 Number 12 • 20 June 2005
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too high to prescribe continuous oxygen therapy but who have
daytime somnolence, daytime hypercapnia, polycythaemia, pulmo-
nary hypertension or right heart failure. The clinical importance of
isolated nocturnal hypoxaemia in COPD is unclear. Although
extrapolation from continuous oxygen therapy studies3,4 might
suggest that such patients would benefit from nocturnal oxygen
supplementation, results of studies have been conflicting. In one
small study, nocturnal oxygen therapy at 3 L/min over 3 years was
associated with a smaller rise in pulmonary artery pressure than in a
control group receiving supplemental air.18 However, there was no
effect on mortality. A larger 2-year study of patients with COPD and
modest daytime hypoxaemia (PaO2 56–69mmHg [7.4–9.2kPa])
who experienced oxygen desaturation to SpO2 < 90% for over 30%
of the night found no survival benefit in the group receiving oxygen
supplementation and no effect on pulmonary haemodynamics.19
The overall mortality rate in the latter study was too small to draw
any definite conclusion, and the treatment group did not consist
entirely of patients with evidence for hypoxic damage. Although
data are insufficient to make rigorous recommendations for this
group, and further studies are needed, the current consensus is that
nocturnal oxygen therapy may be indicated in patients whose
nocturnal arterial oxygen saturation falls below 88% and who have
evidence of hypoxia-related sequelae. Other patients whose oxygen
saturation repeatedly falls below 88% for over a third of the night
may also benefit (E4).
Contraindications for oxygen therapy
Oxygen therapy is not indicated for patients
• with severe airflow limitation whose main complaint is dys-
pnoea but who maintain a PaO2 > 60 mmHg (8 kPa) and who show
no secondary effects of chronic hypoxia;
• who continue to smoke cigarettes (owing to the increased fire
risk and the probability that the poorer prognosis conferred by
smoking will offset treatment benefit);20-22
• who have not received adequate therapy of other kinds (eg,
inhaled and oral bronchodilators and corticosteroids, treatment for
right ventricular failure or for any respiratory infection); and
• who are not sufficiently motivated to undertake the discipline
required for oxygen therapy.
Investigations
The following investigations should be carried out to determine
suitability for domiciliary oxygen therapy.
• Establish the nature and severity of the pulmonary disorder
responsible for hypoxaemia by appropriate testing, including
objective tests of pulmonary function.
• Undertake appropriate clinical, electrocardiographic, echocar-
diographic and radiological assessment of right heart failure and
pulmonary hypertension.
• Measure haematocrit. Polycythaemia, the usual response to
chronic hypoxaemia in otherwise healthy people, is not always
seen in people with hypoxaemia of chronic lung disease. The
degree to which it is adaptive or adds to the burden of disordered
function through increased blood viscosity is controversial. Anae-
mia is always a burden and should be investigated and corrected.
• Undertake other appropriate tests, according to clinical find-
ings, for other major diseases that might be expected to seriously
limit survival. It is appropriate to prescribe oxygen therapy for
symptomatic relief in patients with a very limited prognosis.
Initiation of oxygen therapy
Before introducing oxygen therapy, undertake optimal treatment of
the pulmonary disorder while monitoring improvement with
objective tests such as FEV1 and vital capacity.
10 Treatment may
include maximum therapy for airway obstruction, attention to
nutrition and bodyweight, an exercise rehabilitation program,
control of infection, and treatment of cor pulmonale. When drug
treatment and other therapy has been optimised and the patient’s
condition has stabilised over about 4 weeks, measure PaO2 at rest
and, when indicated, arterial oxygen saturation during sleep. It is
recommended that, before initiating therapy, the goals of treatment
be defined (ie, reversal or prevention of pulmonary hypertension,
improved longevity, symptomatic alleviation of dyspnoea,
improved quality of life) and clearly discussed with the patient.
In patients selected for oxygen therapy, assess the adequacy of
relief of hypoxaemia (PaO2 > 60 mmHg [8 kPa]; SpO2 > 90%) and/
or improvement in exercise capacity or nocturnal arterial oxygen
saturation. If hypercapnia is present at baseline, it will be necessary
to repeat arterial blood gas measurements to ensure there is
minimal rise in PaCO2 and fall in pH in response to supplemental
oxygen.
Reassessment
Patients should be reassessed 1–2 months after starting continuous
or nocturnal oxygen therapy, both clinically and by measurement
of PaO2 and PaCO2. It should then be decided whether the
treatment has been properly applied and whether it is worthwhile
or should be abandoned. Indices that may be used in weighing the
benefits of continuing therapy include whether the patient is
refraining from smoking, whether the patient is finding the
therapy helpful and easily managed, or whether the treatment is
having a negative impact on his or her quality of life. This 1–2-
month review is particularly important to confirm that the low
initial PaO2 was not spurious because the patient was unstable at
the time of sampling. Many patients are prescribed oxygen therapy
because they are hypoxaemic at discharge from hospital after
exacerbation of an underlying respiratory disease, despite an
absence of data to support short-term or longer-term benefits of
oxygen therapy for the individual patients concerned. A New
Zealand study found that 38% of such patients did not fulfil
criteria for long-term oxygen therapy at their 2-month review.23
Reassessment is especially important in this group.
Subsequent review should be undertaken at least annually, or
more often, according to the clinical situation. Arterial blood gas
measurements may be advisable at review to ensure that oxygen
Position on nocturnal oxygen therapy
• Nocturnal oxygen therapy may be indicated to relieve 
demonstrated oxygen desaturation during sleep to SpO2 88% 
(PaO2 < 55 mmHg or 7.3 kPa) for more than a third of the night or in 
the presence of hypoxia-related sequelae (E4).
• The role of continuous positive airway pressure or other ventilatory 
support needs to be considered and may replace or complement 
oxygen therapy. If oxygen therapy is indicated, a concentrator will 
be the least expensive mode of delivery. It can also be used, at 
negligible extra cost, to provide oxygen during daytime exertion.MJA • Volume 182 Number 12 • 20 June 2005 623
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disease. Some patients may show a sustained rise in PaO2 to over
60 mmHg (8 kPa) when breathing air. It has been hypothesised
that this represents the reparative effects of supplementary oxygen
therapy,24 and the consensus is that this should not be a rationale
for stopping therapy.
Patients having intermittent oxygen therapy should also
undergo periodic reassessment, particularly to determine whether
they qualify for continuous oxygen therapy. However, this may be
unnecessary and undesirably disruptive for those with a limited
prognosis.
Quality of life
With the potential restriction of movement imposed by long-term
continuous oxygen therapy, it is possible that the treatment may
only prolong suffering rather than improve quality of life. How-
ever, for patients who qualify for continuous oxygen therapy
according to the above criteria, the improvement in quality of life
will mostly outweigh the restriction imposed. There is some
evidence that women experience more improvement than men in
several quality-of-life dimensions.25,26
Whether oxygen therapy is worthwhile for a particular individ-
ual must be determined by a comprehensive clinical assessment
rather than solely, or mainly, by the increase achieved in PaO2.
Dangers
Pulmonary oxygen toxicity has not been seen at the low rates of
flow used for long-term oxygen therapy. Although supplementary
oxygen in patients with increased PaCO2 may theoretically worsen
hypercapnia, any increase in PaCO2 in patients receiving long-term
oxygen therapy is usually small and well tolerated. In two large
trials of long-term oxygen therapy, hypercapnia was not a problem
— probably because patients were in a stable condition.3,4 How-
ever, serious hypercapnia may occasionally develop, making fur-
ther investigation and consideration of non-invasive ventilation
appropriate. The development of hypercapnia is suggested by an
obvious decrease in respiratory rate and depth, as well as the
development of somnolence and disorientation. The risk appears
greater during acute exacerbations of disease and in patients who
are generally more hypoxaemic.27,28 Sedatives, narcotics, alcohol
and other drugs, which impair the central regulation of breathing,
should not be used in unstable patients with hypercapnia who are
receiving oxygen therapy.
Methods of oxygen delivery
There are three methods of oxygen delivery for the home: oxygen
concentrators, cylinders and liquid oxygen systems.
Concentrators
Oxygen concentrators are floor-standing, electrically driven
devices that entrain room air, extract nitrogen in molecular sieves
and deliver oxygen at the outlet. They run off the domestic
electricity supply, delivering 92% ±3% oxygen when operating at a
flow rate of  4 L/min. The percentage falls with increasing flow
rate (to 90% ±3% oxygen at  5 L/min), depending on the model
of concentrator used.
Small, portable, lightweight, battery-driven oxygen concentra-
tors generating up to 5 L of oxygen per minute are now available
and are potentially suitable for ambulatory use. The currently
available model uses a 12 V battery, and may therefore be run from
a car battery.
Cylinders
Cylinders contain compressed pure oxygen gas and deliver 100%
oxygen. Sizes and contents vary (Box 1). Several portable light-
weight cylinders are available that allow the patient to leave home
for several hours.
Liquid oxygen systems
At very low temperatures, gaseous oxygen may be converted to a
liquid. Liquid oxygen systems conserve space by storing oxygen in
liquid form. The oxygen is delivered through coils, where it
vaporises. Two tanks are needed: a large storage tank, which is
filled by the supplier as required, and a portable unit, filled from
the larger tank for ambulatory use.
Comparison between delivery methods
At the relatively low flow rates employed, there is no significant
difference in the quality of oxygen delivered by the three different
methods. Advantages and disadvantages of each are compared in
Box 2. For most patients receiving continuous or nocturnal oxygen
therapy, concentrators are favoured.
Conservation devices
Conservation devices are designed to maximise the effectiveness of
the delivered oxygen. “Demand flow” devices, which are the most
common, use an electronic sensor to initiate oxygen flow only
during inspiration, ensuring that oxygen is not wasted during
expiration. They are useful cost- and time-conserving devices for
cylinders and liquid oxygen systems, especially portable units. As
these devices switch on flow by sensing negative pressure at the
nares via the nasal cannula, they may not be triggered if the patient
mouth-breathes (unless the cannula is transferred to the mouth).
Many breathless patients become mouth-breathers when they are
more distressed.
Delivery to the patient
All patients should receive careful and detailed instruction on how
to operate and obtain optimal benefit from their oxygen equip-
ment. Flow should be set at the lowest rate needed to maintain a
resting PaO2 of 60 mmHg (in practice, most often 2 L/min). It
should be increased by 1 L/min during exercise and sleep.
Humidifiers are not needed at these low flow rates, as ambient
air entrainment supplies sufficient humidification. Extra soft nasal
prongs are recommended for continuous oxygen use, but may
become uncomfortable at flow rates over 2–3 L/min and in the
1 Cylinder size and capacity
Size Volume (m3)* Use
G 7.6–8.8 Hospital use only
E 3.8–5.2 Lasts about 30 h (flow rate, 2 L/min)
D 1.5 Lasts about 11 h (flow rate, 2 L/min)
C 0.55 Lasts about 3 h (flow rate, 2 L/min)
Traveller 0.257–0.682 Depends on size
* 1m3 = 1000 L.624 MJA • Volume 182 Number 12 • 20 June 2005
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time. Although simple masks may be adequate for many patients,
significant rebreathing, with resulting elevation of PaCO2, may
occur at low flow rates in people with type II respiratory failure,
and Venturi masks may be necessary in this instance.30 The
appropriate mask should be selected based on arterial blood gas
measurements. Both nasal prongs and masks are also acceptable
for intermittent oxygen use.
In selected patients needing continuous high-flow oxygen ther-
apy, transtracheal delivery systems may have advantages.31 These
allow substantially lower flow rates, as the tracheal cannula fills the
tracheal and upper airway dead space with oxygen during each
expiration. However, care of this relatively invasive appliance is
demanding, only a few patients find it an attractive alternative, and
transtracheal delivery is not currently offered routinely in Australia
or New Zealand.
Authorisation of oxygen therapy
Current guidelines for prescription through state-based financial
support programs in Australia and New Zealand usually specify
respiratory physicians and cardiologists as authorised prescribers.
It could be argued that other groups should be authorised, as long
as the guidelines are followed. At present, any registered medical
practitioner may order home oxygen therapy if the patient meets
the costs. State-based funding for concentrator oxygen therapy is
generally provided throughout Australia for patients fulfilling
criteria for long-term continuous oxygen therapy. Some states also
fund ambulatory oxygen therapy to a limited degree, but access
and costs to the patient vary considerably between states. In New
Zealand, the situation is analogous: government-funded concen-
trator oxygen therapy can be authorised only by physicians
designated by the local District Health Board, and ambulatory
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Low cost Most models not portable†
Convenient for home use Electricity required
Wide availability Unreliable with high flow
No delivery problems Risk of mechanical failure
Safe Frequent maintenance needed
Attractive equipment Produces noise and vibration
Cylinders
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High oxygen purity Less convenient for home use
Electricity not required Frequent deliveries needed
Reliable Heavy weight‡
Simple maintenance Small capacity
Much experience (have been 
in use for a long time)
Regular changes of cylinders 
require physical effort
No background noise Unsightly equipment
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